AstraZeneca announced today that Saphnelo (Anifrolumab) has officially been approved by the pharmaceutical supervision and administration bureau of Guangdong Province, and officially introduced into designated medical institutions in the Greater Bay Area for receiving standard treatment but still additional therapy for adult patients with moderate to severe active, antinuclear antibody-positive systemic lupus erythematosus (SLE). Thanks to the Greater Bay Area's "Hong Kong-Macao Medical Device Pass" policy, Anifrolumab has recently landed at the Shenzhen Hospital of the University of Hong Kong. Anifrolumab is the world's first and only approved targeted drug targeting the type I interferon pathway for SLE treatment. (21st Century Business Herald)